Source comparison
Comparison Table: KPV Administration Routes
Subcutaneous 250–500mcg daily 3–7 days Localized inflammation, systemic inflammation Moderate (50–70%) Effective but injection site reactions reported in 25–30% of users; falling out of favor compared to oral/sublingual routes Oral 500–1000mcg daily (split or
This comparison does not assign a generated winner or score.
- Subcutaneous
- 250–500mcg daily
- 3–7 days
- Localized inflammation, systemic inflammation
- Moderate (50–70%)
- Effective but injection site reactions reported in 25–30% of users; falling out of favor compared to oral/sublingual routes
- Oral
- 500–1000mcg daily (split or single dose)
- 10–14 days
- IBD, gut barrier repair, systemic inflammation
- Low to moderate (15–40%)
- Most consistent reported outcomes for GI conditions; split dosing maintains stable anti-inflammatory activity
- Sublingual
- 5–10 days
- Neuroinflammation, autoimmune flares, systemic use
- Moderate to high (40–60%)
- Bypasses first-pass metabolism; requires proper hold time (90–120 seconds) for absorption
- Topical
- 500mcg per application, twice daily
- 5–7 days
- Eczema, psoriasis, rosacea, skin barrier repair
- Site-specific (minimal systemic)
- Excellent for localized skin conditions; minimal systemic absorption limits broader anti-inflammatory effects